Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.57 |
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080451 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL5723882 | 0.86 | OGA (0.52) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL5723854 | 0.85 | GAA (0.48) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3435164 | 0.84 | OGA (0.50) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL15888547 | 0.84 | HRH3 (0.53) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL27149236 | 0.84 | GAA (0.48) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL7185606 | 0.83 | ALDH1A1 (0.62) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL31669107 | 0.83 | ALDH1A1 (0.50) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL15888540 | 0.82 | OGA (0.48) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL10464669 | 0.82 | ALDH1A1 (0.64) | SMN1; SMN2RAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | SMN1; SMN2 3601/4885RAB9A 4401/4885NPC1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.